Jazz Pharmaceuticals plc, of Dublin, said a recently published final appraisal determination from the National Institute for Health and Care Excellence recommended Vyxeos (daunorubicin and cytarabine) for infusion for routine use in the National Health Service in England and Wales for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes.